The national organization of coronary stent set mining agreement expires after the successive purchase 29 bidding, to be selected results, **** 10 enterprises of 14 products to obtain the qualification to be selected. It is expected that in January 2023 patients will use the winning products of the successive purchase.
Figure | State Organization Coronary Stent Centralized Banded Purchasing agreement expires after the succession purchase proposed selection results (Source: State Organization High-Value Medical Consumables Joint Purchasing Office)
The State Medical Insurance Bureau said that this succession purchase for the first time to explore the unified national scope of the work of the succession,*** 3696 medical institutions to participate, compared with the first batch of set of procurement increased by 1288, the medical institutions to fill in the demand for medical institutions, and the medical institutions to participate in the work, and the medical institutions to participate in the work. Medical institutions *** fill in the demand for 1,865,000, 1.7 times more than the first batch of collection and procurement. Compared with the previous round of procurement, the succession of procurement to participate in the medical institutions increased by 40%, the stent procurement volume increased by 30%, the successful enterprises increased by 2, the selected products increased by 4.
Also according to the data, this collection of renewed bids, medical institutions to report the first year of the total procurement needs of 1865057, compared with the first collection of 1074722 in 2020, an increase of about 73.5%. At the same time, the reported volume of domestic manufacturers accounted for about 70.4%, compared with 68.7% market share in 2020 has increased.
In the evening of the same day, Lanshan Medical announced that its wholly-owned subsidiary Jiwei Medical **** has two products to be awarded this centralized volume purchasing. Compared with the first centralized purchasing bidding offer 469 yuan / strip, the company this proposed bidding offer significantly increased to 824 yuan / strip and 845 yuan / strip. The company's EXCROSSAL bracket has become the first set of procurement bidding products in this price increase of the largest products, an increase of more than 75%.
But it is worth noting that look back at 2020 coronary stent first set of procurement, Lanshan Technology subsidiary offer is far lower than peers - according to the data provided by the Guosen Securities report calculations, the average price of the stent to be selected at that time for 675.6 The average price of the selected stent was 675.6 yuan, of which the highest offer was 798 yuan, and the lowest offer came from Jiwei Medical (469 yuan), more than 40% lower than the former.
Figure | 2020 national organization coronary stent centralized volume purchasing to be selected varieties (source: Guoxin Securities report on November 5, 2020, the price from the media public reports)
In addition, if the data in the table, compared to the first set of procurement, the Lepu medical offer rose 31.5%; Wicresoft medical two products quoted prices rose by 23.7 percent respectively, 6.7%, a new product to be selected; Sano Medical added two new products to be selected.
This morning, Lanshan Medical opened up, Sano Medical, Lepu Medical opened higher by 7.35%/5.92% respectively.
Overall, from the collection of the renewal of the collection results, enterprises offer more rational, no longer trying to "low price to win".
On the one hand, the average winning bracket price of about 770 yuan, plus the accompanying service fee, the terminal price range of 730 yuan -848 yuan, compared to the first set of 2020 the average bidding price increased by more than 20%; on the other hand, the gap between the lowest and highest terminal prices . narrowed to around 14%.
Behind this, the set of procurement volume and price linkage is more clear - the succession of procurement according to the offer from low to high order, the proposed winning products are divided into A, B, C three categories, the lower the price to obtain a higher proportion of the portion of the volume, and can be accessed to the pending allocation of more volume.
International Securities today reported that the move fully respects the independent reporting of medical institutions at the same time, but also played a reasonable control of the price of the purpose. And this time, the procurement cycle will be changed from 2 years to 3 years to ensure the stability of the market pattern in a longer period of time.
What does it mean for companies to renew their bids and increase prices today?
Lanfan Technology made it clear in last night's announcement that during the procurement cycle, medical institutions will prioritize the use of this centralized procurement of winning coronary stents and ensure the completion of the agreed procurement volume. If the company subsequently signed the procurement contract and implementation, expected to significantly improve the company's coronary stent products gross profit margin level, the company's profitability has a significant positive impact.
At the same time, Industrial Securities previous research report also gave the view that the head of the coronary stent is expected to innovative products in the field of coronary intervention to form a new point of growth, superimposed on the easing of the traditional stent renewal policy, is expected to usher in the rapid development of the medium and long term. If after the initial set of procurement, manufacturers of coronary production line can still maintain no loss, the renewal of the price increase part are profitable.
The national coronary stent product bandwidth purchasing successive purchasing after the landing, IFC Securities analysts expect that manufacturers are expected to obtain a reasonable profit margin. Future high-value consumables in the field of medical insurance fee-control work in the process of normalization, will be given full consideration to the enthusiasm of the manufacturers of production and supply, medical equipment sector policy sentiment is expected to gradually bottom out .
Throughout the three high-value consumables collection organized by the state, China Merchants Securities believes that, from the coronary stent of the "rate of reduction shall prevail", to the joint implant collection of the new incorporation of the "accompanied by the service fee", to the spine collection of the "rate of reduction to the bottom line". "The rate of reduction of the bottom line", the collection of documents on the ecological and healthy development of the industry's aspirations in order to ensure that the realization of cost control on the basis of the gradual emergence of the industry is conducive to the sustainability of the development of the industry and the localization of the industry, the head of the centralized with a positive effect.